title: Identification of Novel Variant of EML4-ALK Fusion Gene in NSCLC: Potential Benefits of the RT-PCR Method.
abstract: BACKGROUND
  The discovery of the transforming fusion gene of the anaplastic lymphoma kinase (ALK) with the echinoderm microtubule-associated protein like 4 (EML4) as an oncogene in 2007 has led to its validation as a clinical target in NSCLC patients in a short period of time. The inhibition of the anaplastic lymphoma receptor tyrosine kinase has demonstrated to prolong progression-free survival compared to the standard of care chemotherapy in patients with advanced NSCLC that are ALK positive. However, the clinical implications of the 15 different variants of the EML4-ALK transforming gene described so far are currently not defined. Here we present a novel variant of the EML4-ALK fusion gene which we named variant 3c.
  
  
  METHODS
  RNA extracted from formalin fixed paraffin embedded (FFPE) specimens from patients with advanced and metastatic NSCLC was amplified, using primers and probes designed to detect specific EML4-ALK fusion gene fragments. Gel electrophoresis showed a different band for the new variant 3c compared to the known bands of positive cell lines for variant 3a and 3b. These findings were further investigated by dye-terminator Sequencing and FISH.
  
  
  RESULTS
  The novel variant, detected in two NSCLC specimens, is longer than v3a and shorter than v3b, representing an 18 base pair insertion of intron 19 of ALK between exon 6 of EML4 and exon 20 of ALK. All of the two samples showed exactly the same sequencing result. One of the samples was negative for FISH break apart testing and the other one showed a positive result, defined by ≥15% split nuclei as indicative of an ALK rearrangement.
  
  
  CONCLUSIONS
  Compared to FISH technology, RT-PCR enables the detection of different isoforms of the EML4-ALK transforming gene, which can be validated by sequencing. Only one out of two samples that were positive for the new variant by RT-PCR could be confirmed by FISH. The clinical significance of the different variants, notably to resistance and response to ALK-Inhibitors and the concordance and sensitivity of FISH and RT-PCR should be subject to further investigations.
authors.affiliation: Response Genetics, Inc., Los Angeles, CA, USA; ; Department of General, Visceral and Tumor Surgery, University of Cologne, GERMANY;
authors.forename: Martin K H
authors.initials: MK
authors.lastname: Maus
authors.forename: Craig
authors.initials: C
authors.lastname: Stephens
authors.forename: Gary
authors.initials: G
authors.lastname: Zeger
authors.forename: Peter P
authors.initials: PP
authors.lastname: Grimminger
authors.forename: Eric
authors.initials: E
authors.lastname: Huang
keywords: ALK-Inhibitors; EML4-ALK rearrangement; EML4-ALK variants; NSCLC